EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer

Sofia C Vaz iD, John Patrick Pilkington Woll iD, Fatima Cardoso iD, David Groheux iD, Gary J R Cook iD, Gary A Ulaner iD, Heather Jacene iD, Isabel T Rubio iD, Jan W Schoones iD, Marie-Jeanne Vrancken Peeters iD, Philip Poortmans iD, Ritse M Mann iD und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2024-07 · 51 (9) · 2706-2732

DOI: 10.1007/s00259-024-06696-9 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 14.05.2024. Verfasst von Sofia C Vaz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal. sofia.vaz@fundacaochampalimaud.pt. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Breast Neoplasms. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There is much literature about the role of 2-[ 18 F]FDG PET/CT in patients with breast cancer (BC). However, there exists no international guideline with involvement of the nuclear medicine societies about this subject.

Purpose

To provide an organized, international, state-of-the-art, and multidisciplinary guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and representation of important societies in the field of BC (ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA).

Methods

Literature review and expert discussion were performed with the aim of collecting updated information regarding the role of 2-[ 18 F]FDG PET/CT in patients with no special type (NST) BC and summarizing its indications according to scientific evidence. Recommendations were scored according to the National Institute for Health and Care Excellence (NICE) criteria.

Results

Quantitative PET features (SUV, MTV, TLG) are valuable prognostic parameters. In baseline staging, 2-[ 18 F]FDG PET/CT plays a role from stage IIB through stage IV. When assessing response to therapy, 2-[ 18 F]FDG PET/CT should be performed on certified scanners, and reported either according to PERCIST, EORTC PET, or EANM immunotherapy response criteria, as appropriate. 2-[ 18 F]FDG PET/CT may be useful to assess early metabolic response, particularly in non-metastatic triple-negative and HER2+ tumours. 2-[ 18 F]FDG PET/CT is useful to detect the site and extent of recurrence when conventional imaging methods are equivocal and when there is clinical and/or laboratorial suspicion of relapse. Recent developments are promising.

Conclusion

2-[ 18 F]FDG PET/CT is extremely useful in BC management, as supported by extensive evidence of its utility compared to other imaging modalities in several clinical scenarios.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyFluorodeoxyglucose F18Breast NeoplasmsHumansNuclear MedicineFemaleSocieties, Medical

Stichwörter der Autor:innen

2-[18F]FDGBreast cancerEANMNo special typePET/CTSNMMI

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal. sofia.vaz@fundacaochampalimaud.pt.
  • Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. sofia.vaz@fundacaochampalimaud.pt.
  • PET-CT Department, Clinica Delgado AUNA, Lima, Peru.
  • Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Nuclear Medicine Department, Saint-Louis Hospital, Paris, France.
  • University Paris-Diderot, INSERM U976, Paris, France.

ORCID-Profile: Sofia C Vaz, John Patrick Pilkington Woll, Fatima Cardoso, David Groheux, Gary J R Cook, Gary A Ulaner, Heather Jacene, Isabel T Rubio, Jan W Schoones, Marie-Jeanne Vrancken Peeters, Philip Poortmans, Ritse M Mann, Stephanie L Graff, Elizabeth H Dibble, Lioe-Fee de Geus-Oei

Zitieren

APA

Vaz, S. C., Woll, J. P. P., Cardoso, F., Groheux, D., Cook, G. J. R., Ulaner, G. A., Jacene, H., Rubio, I. T., Schoones, J. W., Peeters, M. V., Poortmans, P., Mann, R. M., Graff, S. L., Dibble, E. H., & de Geus-Oei, L. F. (2024). Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 51(9), 2706-2732. https://doi.org/10.1007/s00259-024-06696-9

Vancouver

Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(9):2706-2732. doi:10.1007/s00259-024-06696-9

BibTeX
@article{Vaz2024,
  author = {Vaz, Sofia C and Woll, John Patrick Pilkington and Cardoso, Fatima and Groheux, David and Cook, Gary J R and Ulaner, Gary A and Jacene, Heather and Rubio, Isabel T and Schoones, Jan W and Peeters, Marie-Jeanne Vrancken and Poortmans, Philip and Mann, Ritse M and Graff, Stephanie L and Dibble, Elizabeth H and de Geus-Oei, Lioe-Fee},
  title = {Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  volume = {51},
  number = {9},
  pages = {2706--2732},
  doi = {10.1007/s00259-024-06696-9}
}
Kostenlos starten →